Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical ... News-Medical.net "We are encouraged by the preliminary single-agent activity and tolerability demonstrated by SGN-75 in RCC patients and by our preclinical data suggesting synergy between auristatin-containing ADCs and mTOR inhibitors, including everolimus. We look ... Seattle Genetics Begins Phase Ib study Of SGN-75 Combined With Everolimus Seattle Genetics (SGEN) Starts Phase 1B Kidney Cancer Trial Seattle Genetics Announces Initiation Of A Phase Ib Trial Of SGN-75 In ... |
